Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Liver Fibrosis Due to NASH

In brief

The primary objective of this study is to evaluate the safety and efficacy of SIM (formerly referred to as GS-6624) in adults with compensated cirrhosis due to Non-Alcoholic Steatohepatitis (NASH). It will consist of 2 phases: * Randomized Double-Blind Phase * Open-Label Phase (optional)

Key facts

Study ID
NCT01672879
Run by
Gilead Sciences
People needed
259
Starts
2012-10-29
Expected to finish
2017-01-03
Last updated by the study team
2019-03-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.